Research & Development

Inimune technology focuses on the discovery, optimization and development of new immunomodulatory therapeutics for the treatment or prevention of allergy, autoimmunity, upper respiratoty tract infections and cancer, by targeting innate immune receptors.

Inimmune technology is focused on the discovery, optimization and development of new innate immune receptor agonists and antagonists to treat a wide array of medical conditions including allergies, autoimmune diseases, upper respiratory tract infections and cancer.

Through structure-activity relationship (SAR) studies, molecular modeling and design, formulation development and in vitro / in vivo immunologic testing, Inimmune is developing more potent, selective, efficacious and safe immunomodulators.

Allergies are among the most common chronic conditions worldwide. Allergies are a number of conditions caused by hypersensitivity of the immune system to something in the environment that usually causes little problem in most people.

Allergies include hay fever, food allergies, atopic dermatitis, allergic asthma, insect stings. Symptoms may include red eyes, an itchy rash, runny nose, shortness of breath, or swelling. The severity of allergies varies from person to person and can range from minor irritation to anaphylaxis — a potentially life-threatening emergency.

While most allergies can’t be cured, a number of treatments can help relieve allergy symptoms. Inimmune is developing technology that redirects the immune response caused by allergens to counteract and eliminate the allergic response.

An autoimmune disease results from a malfunction in the immune system where healthy cells are mistaken for foreign invaders, causing the immune system to attack these healthy cells.

According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease affects up to 50 million Americans. Autoimmune diseases include rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and type I diabetes among many others. Currently, treatment for autoimmune diseases focuses on relieving symptoms because there is no curative therapy.

Inimmune is developing technology that may interrupt the chain of events involved in autoimmune disease by targeting specific receptors involved in the autoimmune disease.

Image adapted from http://healthfactsdirectory.com/autoimmune-disease-what/

Upper respiratory tract infections (URI or URTI) are illnesses caused by an acute infection which involves the upper respiratory tract including the nose, sinuses, pharynx or larynx. This commonly includes tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, and the common cold.

The vast majority of upper respiratory infections are caused by respiratory viruses (rhinoviruses, influenza virus, respiratory syncytial virus) and are self-limited. But in people suffering from asthma and COPD, URTI infections are the major cause of exacerbations of disease and can require acute care.

Inimmune is developing immunomodulators that induce broad antiviral innate immunity for the reduction of viral URT and associated exacerbations in asthma and COPD patients.

Skin cancer is the most common form of cancer in the United States. With over 3.5 million new diagnoses annually in the United States, basal cell carcinomas (BCC) and squamous cell carcinomas (SCS) are the two most prevalent non-melanoma skin cancers (NMSC).

Melanoma is the third most common skin cancer, comprising 5-7% of all skin cancer diagnosis, with 76,000 new cases diagnosed in 2012. Importantly, melanoma leads to over 9,000 deaths annually accounting for the majority of skin cancer deaths. Inimmune is developing topical antitumor therapeutics for the treatment of malignant skin disease targeting specific receptors involved in skin cancer.

Image adapted from http://dyersburgskinandallergyclinic.com/?p=311

Copyright © 2015 Inimmune